Cetuximab therapy in the treatment of metastatic colorectal cancer: The future frontier?

International Journal of Surgery

Volumn 11, Issue 7, 2013, Pages 507-513

  Gomez, D ^a   De Rosa, A ^a   Addison, A ^a   Brooks, A ^a   Malik, H Z ^b   Cameron, I C ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

^b ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Cetuximab; Colorectal cancer; Hepatectomy; Liver metastases

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN;

CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; COLORECTAL CANCER; HUMAN; LIVER METASTASIS; LIVER RESECTION; METASTATIC COLORECTAL CANCER; MORBIDITY; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT RESPONSE;

CETUXIMAB; COLORECTAL CANCER; HEPATECTOMY; LIVER METASTASES;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; HEPATECTOMY; HUMANS; LIVER NEOPLASMS;

EID: 84880325922     PISSN: 17439191     EISSN: 17439159     Source Type: Journal    
DOI: 10.1016/j.ijsu.2013.04.014     Document Type: Review

References (48)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55(2):74-108.
2. O'Connell J.B., Maggard M.A., Ko C.Y. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004, 96(19):1420-1425.
3. Fernandez F.G., Drebin J.A., Linehan D.C., Dehdashti F., Siegel B.A., Strasberg S.M. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 2004, 240(3):438-447. discussion 447-450.
4. Tomlinson J.S., Jarnagin W.R., DeMatteo R.P., Fong Y., Kornprat P., Gonen M., et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 2007, 25(29):4575-4580.
5. Gomez D., Morris-Stiff G., Wyatt J., Toogood G.J., Lodge J.P., Prasad K.R. Surgical technique and systemic inflammation influences long-term disease-free survival following hepatic resection for colorectal metastasis. J Surg Oncol 2008, 98(5):371-376.
6. Alberts S.R., Horvath W.L., Sternfeld W.C., Goldberg R.M., Mahoney M.R., Dakhil S.R., et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 2005, 23(36):9243-9249.
7. Pozzo C., Basso M., Cassano A., Quirino M., Schinzari G., Trigila N., et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 2004, 15(6):933-939.
8. Porebska I., Harlozinska A., Bojarowski T. Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. Tumour Biol 2000, 21(2):105-115.
9. Ciardiello F., Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001, 7(10):2958-2970.
10. Lenz H.J., Van Cutsem E., Khambata-Ford S., Mayer R.J., Gold P., Stella P., et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. JClin Oncol 2006, 24(30):4914-4921.
11. Lievre A., Bachet J.B., Boige V., Cayre A., Le Corre D., Buc E., et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008, 26(3):374-379.
12. De Roock W., Claes B., Bernasconi D., De Schutter J., Biesmans B., Fountzilas G., et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010, 11(8):753-762.
13. Di Fiore F., Blanchard F., Charbonnier F., Le Pessot F., Lamy A., Galais M.P., et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007, 96(8):1166-1169.
14. Khambata-Ford S., Garrett C.R., Meropol N.J., Basik M., Harbison C.T., Wu S., et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007, 25(22):3230-3237.
15. Karapetis C.S., Khambata-Ford S., Jonker D.J., O'Callaghan C.J., Tu D., Tebbutt N.C., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008, 359(17):1757-1765.
16. Cunningham D., Humblet Y., Siena S., Khayat D., Bleiberg H., Santoro A., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351(4):337-345.
17. Saltz L.B., Meropol N.J., Loehrer P.J., Needle M.N., Kopit J., Mayer R.J. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004, 22(7):1201-1208.
18. Pessino A., Artale S., Sciallero S., Guglielmi A., Fornarini G., Andreotti I.C., et al. First-line single-agent cetuximab in patients with advanced colorectal cancer. Ann Oncol 2008, 19(4):711-716.
19. Jonker D.J., O'Callaghan C.J., Karapetis C.S., Zalcberg J.R., Tu D., Au H.J., et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007, 357(20):2040-2048.
20. Sobrero A.F., Maurel J., Fehrenbacher L., Scheithauer W., Abubakr Y.A., Lutz M.P., et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26(14):2311-2319.
21. Maughan T.S., Adams R.A., Smith C.G., Meade A.M., Seymour M.T., Wilson R.H., et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011, 377(9783):2103-2104.
22. Pfeiffer P., Nielsen D., Bjerregaard J., Qvortrup C., Yilmaz M., Jensen B. Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil. Ann Oncol 2008, 19(6):1141-1145.
23. Koo D.H., Lee J.L., Kim T.W., Chang H.M., Ryu M.H., Lee S.S., et al. A Phase II study of cetuximab (Erbitux) plus FOLFIRI for irinotecan and oxaliplatin-refractory metastatic colorectal cancer. J Korean Med Sci 2007, 22(Suppl):S98-S103.
24. Wilke H., Glynne-Jones R., Thaler J., Adenis A., Preusser P., Aguilar E.A., et al. Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study. J Clin Oncol 2008, 26(33):5335-5343.
25. Vincenzi B., Santini D., Rabitti C., Coppola R., Beomonte Zobel B., Trodella L., et al. Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial. Br J Cancer 2006, 94(6):792-797.
26. Lim R., Sun Y., Im S.A., Hsieh R.K., Yau T.K., Bonaventura A., et al. Cetuximab plus irinotecan in pretreated metastatic colorectal cancer patients: the ELSIE study. World J Gastroentero 2011, 17(14):1879-1888.
27. Buzaid A.C., Mathias Cde C., Perazzo F., Simon S.D., Fein L., Hidalgo J., et al. Cetuximab Plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan: the LABEL study. Clin Colorectal Cancer 2010, 9(5):282-289.
28. Souglakos J., Kalykaki A., Vamvakas L., Androulakis N., Kalbakis K., Agelaki S., et al. Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy. Ann Oncol 2007, 18(2):305-310.
29. Ocvirk J., Brodowicz T., Wrba F., Ciuleanu T.E., Kurteva G., Beslija S., et al. Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. World J Gastroenterol 2011, 16(25):3133-3143.
30. Tabernero J., Van Cutsem E., Diaz-Rubio E., Cervantes A., Humblet Y., Andre T., et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2007, 25(33):5225-5232.
31. Van Cutsem E., Kohne C.H., Hitre E., Zaluski J., Chang Chien C.R., Makhson A., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009, 360(14):1408-1417.
32. Folprecht G., Gruenberger T., Bechstein W.O., Raab H.R., Lordick F., Hartmann J.T., et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2011, 11(1):38-47.
33. Garufi C., Torsello A., Tumolo S., Ettorre G.M., Zeuli M., Campanella C., et al. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. Br J Cancer 2011, 103(10):1542-1547.
34. Arnold D., Hohler T., Dittrich C., Lordick F., Seufferlein T., Riemann J., et al. Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. Ann Oncol 2008, 19(8):1442-1449.
35. Raoul J.L., Van Laethem J.L., Peeters M., Brezault C., Husseini F., Cals L., et al. Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. BMC Cancer 2009, 9:112.
36. Bokemeyer C., Bondarenko I., Makhson A., Hartmann J.T., Aparicio J., de Braud F., et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009, 27(5):663-671.
37. Borner M., Koeberle D., Von Moos R., Saletti P., Rauch D., Hess V., et al. Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. Ann Oncol 2008, 19(7):1288-1292.
38. Giacchetti S., Bjarnason G., Garufi C., Genet D., Iacobelli S., Tampellini M., et al. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. J Clin Oncol 2006, 24(22):3562-3569.
39. Levi F.A., Zidani R., Vannetzel J.M., Perpoint B., Focan C., Faggiuolo R., et al. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst 1994, 86(21):1608-1617.
40. Levi F., Zidani R., Misset J.L. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lancet 1997, 350(9079):681-686.
41. Levi F., Karaboue A., Gorden L., Innominato P.F., Saffroy R., Giacchetti S., et al. Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability. Cancer Chemother Pharmacol 2011, 67(2):339-348.
42. Folprecht G., Grothey A., Alberts S., Raab H.R., Kohne C.H. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005, 16(8):1311-1319.
43. Meyerhardt J.A., Heseltine D., Ogino S., Clark J.W., Enzinger P.C., Ryan D.P., et al. Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer. Clin Colorectal Cancer 2006, 6(1):59-65.
44. Pfeiffer P., Nielsen D., Yilmaz M., Iversen A., Vejlo C., Jensen B.V. Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil. Acta Oncol 2007, 46(5):697-701.
45. Martin-Martorell P., Rosello S., Rodriguez-Braun E., Chirivella I., Bosch A., Cervantes A. Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial. Br J Cancer 2008, 99(3):455-458.
46. Folprecht G., Lutz M.P., Schoffski P., Seufferlein T., Nolting A., Pollert P., et al. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 2006, 17(3):450-456.
47. Adam R., Aloia T., Levi F., Wicherts D.A., de Haas R.J., Paule B., et al. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol 2007, 25(29):4593-4602.
48. Brouquet A., Overman M.J., Kopetz S., Maru D.M., Loyer E.M., Andreou A., et al. Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?. Cancer 2011, 117(19):4484-4492.